# Canrenone as Add-on in Patients With Essential Hypertension

Study · id `cardio:ct-nct02687178` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02687178](<https://clinicaltrials.gov/study/NCT02687178>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02687178

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

## Technical summary

Registry record NCT02687178. Randomized; no masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2015-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 180 participants (enrolled count; ClinicalTrials.gov record NCT02687178, source copy `cardio:ctgov-nct02687178-2016-04-01`, retrieved 2026-10-26)
- Start date: 2010-10 (registry gives no type) (ClinicalTrials.gov record NCT02687178, source copy `cardio:ctgov-nct02687178-2016-04-01`, retrieved 2026-10-26)
- Primary completion: 2015-10 (actual) (ClinicalTrials.gov record NCT02687178, source copy `cardio:ctgov-nct02687178-2016-04-01`, retrieved 2026-10-26)
- Completion: 2016-01 (actual) (ClinicalTrials.gov record NCT02687178, source copy `cardio:ctgov-nct02687178-2016-04-01`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02687178-2016-04-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Canrenone as Add-on in Patients With Essential Hypertension
- Condition: Essential Hypertension
- Intervention (Drug): Canrenone 50 vs canrenone 100 mg
- Lead sponsor: University of Pavia
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: University of Pavia (`cardio:org-university-of-pavia`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial (`cardio:pubmed-27860389`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 96e61fdabad4c620d40bcdb79eb7673ad6244a9ce866e81f101cacc5f960e774
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
